Incidence of post-transplant cytomegalovirus viremia in patients receiving lungs after ex vivo lung perfusion.
CMV viremia
ex vivo lung perfusion
freedom from CMV
lung transplantation
Journal
JTCVS open
ISSN: 2666-2736
Titre abrégé: JTCVS Open
Pays: Netherlands
ID NLM: 101768541
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
25
10
2022
revised:
07
02
2023
accepted:
13
02
2023
medline:
10
7
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
epublish
Résumé
Cytomegalovirus infection after lung transplant is associated with increased morbidity and mortality. Inflammation, infection, and longer ischemic times are important risk factors for cytomegalovirus infection. Ex vivo lung perfusion has helped to successfully increase the use of high-risk donors over the last decade. However, the impact of ex vivo lung perfusion on post-transplant cytomegalovirus infection is unknown. We performed a retrospective analysis of all adult lung transplant recipients from 2010 to 2020. The primary end point was comparison of cytomegalovirus viremia between patients who received ex vivo lung perfusion donor lungs and patients who received non-ex vivo lung perfusion donor lungs. Cytomegalovirus viremia was defined as cytomegalovirus viral load greater than 1000 IU/mL within 2 years post-transplant. Secondary end points were the time from lung transplant to cytomegalovirus viremia, peak cytomegalovirus viral load, and survival. Outcomes were also compared between the different donor recipient cytomegalovirus serostatus matching groups. Included were 902 recipients of non-ex vivo lung perfusion lungs and 403 recipients of ex vivo lung perfusion lungs. There was no significant difference in the distribution of the cytomegalovirus serostatus matching groups. A total of 34.6% of patients in the non-ex vivo lung perfusion group developed cytomegalovirus viremia, as did 30.8% in the ex vivo lung perfusion group ( The practice of using more injured donor organs via ex vivo lung perfusion has not affected cytomegalovirus viremia rates and severity in lung transplant recipients in our center.
Identifiants
pubmed: 37425481
doi: 10.1016/j.xjon.2023.02.008
pii: S2666-2736(23)00034-7
pmc: PMC10328819
doi:
Types de publication
Journal Article
Langues
eng
Pagination
590-601Informations de copyright
© 2023 The Author(s).
Références
Transpl Infect Dis. 2018 Oct;20(5):e12964
pubmed: 29981174
N Engl J Med. 2011 Apr 14;364(15):1431-40
pubmed: 21488765
Virology (Auckl). 2019 Apr 02;10:1178122X19840371
pubmed: 30983861
J Heart Lung Transplant. 2008 Jun;27(6):662-7
pubmed: 18503967
Transpl Int. 2010 Jun;23(6):628-35
pubmed: 20059752
Infect Chemother. 2013 Sep;45(3):260-71
pubmed: 24396627
Am J Transplant. 2004 Aug;4(8):1219-26
pubmed: 15268722
Am J Respir Crit Care Med. 2010 Jun 15;181(12):1391-6
pubmed: 20167845
Clin Infect Dis. 1998 Mar;26(3):753-5
pubmed: 9524855
Transplantation. 1994 Sep 27;58(6):675-80
pubmed: 7940686
J Thorac Dis. 2014 Aug;6(8):1054-62
pubmed: 25132972
Transpl Infect Dis. 2001 Sep;3(3):128-37
pubmed: 11493395
Am J Transplant. 2005 Jun;5(6):1462-8
pubmed: 15888055
PLoS One. 2014 Jun 11;9(2):e98819
pubmed: 24919177
FEMS Microbiol Rev. 1999 Jul;23(4):457-82
pubmed: 10422262
J Heart Lung Transplant. 2011 Sep;30(9):990-6
pubmed: 21489817
J Virol. 1993 Sep;67(9):5360-6
pubmed: 8394453
J Heart Lung Transplant. 2022 Mar;41(3):287-297
pubmed: 34802874
Rev Med Virol. 2016 Mar;26(2):75-89
pubmed: 26572645
Am J Transplant. 2009 Dec;9 Suppl 4:S78-86
pubmed: 20070700
Rev Med Virol. 2019 May;29(3):e2034
pubmed: 30706584
Front Cell Infect Microbiol. 2020 Mar 31;10:130
pubmed: 32296651
JAMA Surg. 2019 Dec 1;154(12):1143-1150
pubmed: 31596484
Clin Infect Dis. 2004 Nov 1;39(9):1293-9
pubmed: 15494905
J Thorac Dis. 2020 Apr;12(4):1350-1356
pubmed: 32395272
PLoS One. 2017 Jan 27;12(1):e0171035
pubmed: 28129395